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Tumor-initiating cells (TICs) are thought to be critical for promoting tumorigenesis. In a recent Cell article,
Zhang and colleagues found that non-small cell lung cancer TICs overexpress the metabolic enzyme glycine
decarboxylase, which leads to increases in pyrimidine synthesis and is critical for proliferation and tumor
initiation.Tumors are frequently composed of a
heterogeneous population of cancer
cells, and accumulating evidence sug-
gests that, in many tumor types, only a
subpopulation of these cells, named can-
cer stem cells or tumor-initiating cells
(TICs) (Nguyen et al., 2012), are respon-
sible for tumor maintenance and pro-
gression. There is also evidence that
TICs are more resistant to many conven-
tional chemotherapies and radiotherapies
and, as such, are suspected to be re-
sponsible for tumor recurrence after
treatment (Singh and Settleman, 2010).
Hence, understanding the vulnerabilities
of TICs could enable more effective
cancer therapies.
Within this context, Zhang et al., (2012)
describe the isolation of TICs from non-
small cell lung cancer (NSCLC) and char-
acterization of some of the TICs’ uni-
que phenotypic features in a recent Cell
article. Remarkably, NSCLC TICs have
robust increases in glycolysis as well as
in glycine/serine metabolism, most nota-
bly at the level of the glycine cleavage
system enzyme, leading to increased
pyrimidine synthesis and proliferation.
This study supports a large body of work
indicating that cancer cells differ from
non-transformed cells in their program-
ming for nutrient metabolism (Ferreira
et al., 2012).
In a very deft series of experiments,
Zhang et al., (2012) report that within the
otherwise heterogeneous NSCLCs, there
exists a subpopulation of CD166+ cells
that are extremely potent in their abilityto induce tumor formation in immuno-
compromised NOD/SCID Il2rg/ mice
and form tumor spheres in vitro. As
such, they can be considered TICs. Yet
another remarkable feature of the TICs is
their metabolic profile. Concomitant with
an upregulation of glycolytic genes, there
is also a strong upregulation of genes
involved in serine, glycine, and one-
carbon metabolism. Intracellular metabo-
lite levels from TICs accord well with the
gene expression profiles, as there is
a relative increase in glycolytic inter-
mediates as well as intermediates associ-
ated with glycine/serine and nucleotide
metabolism. Among all of the gene
expression changes observed in TICs,
the most striking one is a powerful in-
crease in glycine decarboxylase (GLDC),
a member of the protein complex
that catabolizes glycine into carbon
dioxide, ammonia, and 5,10-methylene-
tetrahydrofolate.
Convincingly, Zhang et al., (2012)
showed that GLDC overexpression pro-
motes glycolysis, serine/glycine metabo-
lism, and the accumulation of pyrimidine
nucleotides. Consistent with the idea
that the deviant serine/glycine metabo-
lism of TICs facilitates their tumorigenic
capacity, CD166 lung tumor cells, which
are otherwise non-tumorigenic, were able
to establish tumors at low frequency
when made to overexpress GLDC. Fur-
thermore, GLDC overexpression alone
was able to transform NIH 3T3 cells
in vitro and drive tumor formation in vivo,
which required GLDC’s enzymatic activityCancer Cell 21,to be intact. Knockdown of this enzyme,
on the other hand, was effective in di-
minishing many of these parameters,
including tumorigenicity, in cells that
express high levels of GLDC. Together,
these results suggest that GLDC could
be a new NSCLC oncogene—a finding
that will be strengthened if recurrent ge-
nomic alterations that increase GLDC
activity are found in primary tumors. The
potential clinical relevance of GLDC over-
expression in NSCLC was given further
salience by the revelation that high
expression of GLDC in primary NSCLC
tumors is significantly associated with a
higher risk of patient mortality.
Although originally identified in TICs
derived from primary lung tumors, Zhang
et al., (2012) also show that GLDC is
expressed at high levels in many other
tumor types and in about 25% of cancer
cell lines tested. Knockdown of GLDC in
these high expressing cell lines, such as
A549 lung adenocarcinoma cells and
CACO2 colon cancer cells, reduces their
proliferation and tumorigenic potential.
Importantly, to demonstrate that this is
a newly acquired vulnerability of these
cancer cell lines and not an activity that
is generally required for proliferation,
Zhang et al., (2012) showed that GLDC
knockdown did not affect the proliferation
of normal human lung fibroblasts. They
also hint on the possibility of exploiting
this new metabolic vulnerability for
therapeutic purposes by showing that
cells that overexpress this enzyme are
more sensitive to the antifolate drugFebruary 14, 2012 ª2012 Elsevier Inc. 143
Figure 1. A Summary of the Protein Constituents of the Glycine Cleavage Complex and the
Reactions that They Catalyze
The oxidative decarboxylation and deamination of glycine begins with glycine decarboxylase (GLDC;
P protein), which removes carbon dioxide from glycine and transfers amethylamine group to the dithiolane
ring of a lipoic acid molecule attached to H protein. The methylamine moiety is transferred to tetrahydro-
folate (THF) by T protein, generating 5,10-methylene-tetrahydrofolate and reduced lipoate-H protein in the
process. The reduced lipoate group of H protein is subsequently oxidized by L protein using NAD+. This
reaction regenerates the dithiolane ring of H protein’s lipoate functional group, permitting it to participate
in another catalytic cycle. Reducing equivalents in the form of NADH, one-carbon groups in the form of
5,10-methylene-THF and ammonium are important products of this reaction system. Based upon the
work of Zhang et al., (2012), it is the enhanced supply of 5,10-methylene-THF available for use in the
one-carbon cycle as well as for the synthesis of pyrimidines whereby upregulation of GLDC promotes
tumor initiation.
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Previewsmethotrexane. It will be interesting to
investigate if GLDC expression is a
predictor of response to antifolate drugs
in some cancers.
The work presented by Zhang et al.,
(2012) is a technical tour-de-force for
its isolation of a rare subpopulation
of TICs from primary NSCLC and for
providing the scientific community with
an explanation for what is genetically
and metabolically unique about them.
Although it certainly adds to our under-
standing about the metabolic differences
between cancerous and non-cancerous
cells, it also raised several fascinating
questions.
The first—and most general—question
concerns the nature of the recurring asso-
ciation between serine/glycine metabo-
lism and tumorigenesis/cell proliferation.
Other groups have also reported that
many cancers have elevated levels of en-
zymes involved in the processing of
serine/glycine (Possemato et al., 2011;
Locasale et al., 2011; Vazquez et al.,144 Cancer Cell 21, February 14, 2012 ª20122011; Vie´ et al., 2008), and overexpres-
sion of some of these enzymes is suffi-
cient to enhance the potential for cellular
transformation and/or increase the rate
of cellular proliferation (Locasale et al.,
2011; Vie´ et al., 2008). How does an
increase in this pathway facilitate prolif-
eration and tumorigenesis? Does it pro-
vide extra pyrimidines for DNA replication
and prevent uracil accumulation? Are
there epigenetic effects on proliferative
gene expression, perhaps due to changes
in one-carbon metabolism and cellular
methylation capacity? Or are there other
explanations? The metabolic fate of the
amino acids serine and glycine is com-
plexly intertwined with pathways associ-
ated with the TCA cycle, glycolysis,
protein synthesis, generation of interme-
diates for one-carbon metabolism, phos-
pholipid synthesis, nucleotide synthesis,
and maintenance of cellular osmolarity.
Carefully dissecting the contribution of
changes in the flux of these subsidiary
metabolic pathways as a consequenceElsevier Inc.of a change in the rate in which a cell
processes serine/glycine is an arduous
task and will require more than a simple
measurement of steady-state metabolite
levels—an often deceptive marker of
both the rate and directionality of flux
(Fell, 1992; Snell and Fell, 1990). This later
point is particularly important when
evaluating the serine/glycine pathway,
as many of the enzymes operate with
only a slight displacement from equilib-
rium and flux determining steps are not
intuitive.
The second question, as a corollary to
the first, is how upregulated flux through
the serine/glycine pathway is sustained
in cancerous cells given all of the feed-
back mechanisms that are present in
normal cells that prevent excess cycling
through this pathway. Zhang et al.,
(2012) provide a tantalizing hint that, at
least in the case of GLDC, oncogenes
may drive the chronically high expression
of serine/glycine metabolic enzymes, but
how this occurs is unknown.
Finally, in regard to the biology of
GLDC, it is curious that overexpression
of only one component of the glycine
cleavage complex is sufficient to mas-
sively perturb glycine dissimilation (Fig-
ure 1). The glycine cleavage complex is
a multi-enzyme complex composed of
four different subunits (P-[aka, GLDC]
and H-, T-, and L-subunits) that are pre-
sent in a ratio of 2P:27H:9T:1L and coop-
erate to channel substrates to reaction
completion. Given this information, why
are other subunits of the glycine cleavage
complex not elevated in TICs? Is there
a stoichiometric deficiency of GLDC in
non-TICs that normally limits flux through
the glycine cleavage complex? Is there
a rearrangement of the complex ratios or
modifications to the constituent subunits
to handle an increase in GLDC-mediated
product formation?
Overall, the paper presented by Zhang
et al., (2012) makes a number of important
contributions toward our understanding
of the genetic and metabolic hetero-
geneity that is found in the cells within
human tumors. It also suggests that inhi-
bition of GLDC can be used in conjunction
with existing antifolate chemotherapeutic
regiments for the treatment of certain
types of cancer. We shall watch with great
interest as the story behind serine/glycine
metabolism in cancer unfolds over the
coming years.
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MYCN is an oncogenic driver of childhood neuroblastoma, a frequently lethal pediatric tumor. In a recent
paper in Science Translational Medicine, Chanthery and colleagues demonstrate that PI3K inhibition leads
to the dual therapeutic benefits of enhanced MYCN degradation and loss of a paracrine angiogenic signal
mediated by MYCN.Despite decades of ever-improving
outcomes across diverse pediatric
cancers, neuroblastoma has remained a
frustrating clinical entity. Most children
are diagnosed with tumors that harbor
genetic and biological features highly
correlated with a poor treatment out-
come. Current therapy for such high-risk
patients includes dose-intensive chemo-
therapy, radiotherapy, and retinoids.
Though there have been recent impres-
sive translational successes for this
tumor, such as immunotherapy using
an antibody targeting cell-surface GD2
given with immunostimulatory cytokines
(Yu et al., 2010), 3 year relapse free
survival estimates for high-risk disease
remain under 50%.
Further compounding the frustration is
the fact that the genome of neuroblas-
toma is one of the most comprehensively
characterized among pediatric cancers,
but it has not yet led to more effective
treatment. The recent discovery that the
ALK receptor tyrosine kinase is constitu-
tively activated in 10% of neuroblas-
tomas (Mosse´ et al., 2008) provides onesuch therapeutic opportunity, as ALK
inhibitors have been in development due
to the involvement of this kinase in a
subset of non-small-cell lung cancers
and anaplastic lymphomas. First genera-
tion ALK inhibitors such as crizotinib are
already in Phase 2 trials for children with
relapsed or refractory neuroblastoma
and may make their way soon into upfront
therapy for those patients with ALK-
mutated tumors.
Contrast that withMYCN, the only other
bona fide oncogene yet discovered in
neuroblastoma that was initially identified
almost 30 years ago (Brodeur et al., 1984).
Despite this lead-time and a great deal of
effort, no therapeutic has yet emerged to
be able to target this clear oncogenic
driver of the most aggressive subset
of neuroblastomas. MYCN, which is a
homolog of the MYC proto-oncogene, is
somatically amplified in the tumor cells
of 20% of neuroblastoma patients (and
in 40% of those with a high-risk pheno-
type). MYCN amplification is indepen-
dently correlated with advanced stage
disease and poor outcome and thereforeis used worldwide in risk classification
algorithms. Moreover, genetically engi-
neered mouse models with MYCN ex-
pression targeted to neural crest tissue
develop tumors that resemble human
neuroblastoma (Weiss et al., 1997). MYC
proteins, including MYCN, serve pleio-
tropic roles in malignancy, such as
altering metabolic programs, supporting
angiogenesis, promoting self-renewal
and ‘‘stemness,’’ and driving proliferation
while inhibiting differentiation.
ALK as a kinase is a pharmacologically
tractable target, and a wealth of experi-
ence suggests that inhibition of activated
kinases can lead to clinically impressive
tumor responses. MYCN, in contrast,
has long been seen as a problematic
therapeutic target, as inactivating a highly
abundant nuclear transcription factor that
operates through a network of protein-
protein interactions is pharmacologically
daunting. Still, tumors are remarkably
heterogeneous and cancer cells are
remarkably adaptive. Resistance to tar-
geted therapeutics can be efficiently
selected for, especially when cells haveFebruary 14, 2012 ª2012 Elsevier Inc. 145
